Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening

Hossein Poustchi ¹, Fariba Alaei-Shahmiri ², Rokhsareh Aghili ², Sohrab Nobarani ², Mojtaba Malek ³, Mohammad E. Khamseh ² *

Cited by CrossRef: 4

1- En Li Cho E, Ang C, Quek J, Fu C, Lim L, Heng Z, Tan D, Lim W, Yong J, Zeng R, Chee D, Nah B, Lesmana C, Bwa A, Win K, Faulkner C, Aboona M, Lim M, Syn N, Kulkarni A, Suzuki H, Takahashi H, Tamaki N, Wijarnpreecha K, Huang D, Muthiah M, Ng C, Loomba R. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138 [Crossref]

2- Cazac G, Lăcătușu C, Mihai C, Grigorescu E, Onofriescu A, Mihai B. Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines. 2022;10(10):2375 [Crossref]

3- Khamseh M, Malek M, Jahangiri S, Nobarani S, Hekmatdoost A, Salavatizadeh M, Soltanieh S, Chehrehgosha H, Taheri H, Montazeri Z, Attaran F, Ismail-Beigi F, Alaei-Shahmiri F. Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis. Dig Dis Sci. 2024;69(4):1430 [Crossref]

4- Malek M, Khamseh M, Chehrehgosha H, Nobarani S, Alaei-Shahmiri F. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. Endocrine. 2021;74(3):538 [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.